Lai Wang

President, Global Head of R&D · BeOne Medicines

Lai Wang (President, Global Head of R&D) filed 4 Form 4 reports in the trailing twelve months (0 purchases, 4 sales), most often in BeOne Medicines AG (ONC). The largest single filing was $357K of ONC (1,327 sh × $269.34, as filed), executed Jun 8. Data as of Nov 8 2026.

Add to watchlist

Return, ttmiAverage return per filing, trailing twelve months

–

no purchases on file

Delay-adjustediThe same average, entered at disclosure dates

–

returns measure stock purchases only

Filings, ttm

0 buys · 4 sells

Median delay

–

measured on stock purchases

Volume, ttmiDollar value disclosed in the trailing twelve months

$1.2M

shares × price, as filed

Last traded

Jun 23

Filed Jun 25

Median ADV $130.5M across their filed names

Open performance→

Volume by month

Buys $0 Sells $6.4M

Shares × price, as filed · by filing month · past 24 months

Sectors filed on

Healthcare 4 filings

Sector per market data · by filing · past 12 months

Most traded names

ONC

BeOne Medicines AG ONC · 0 buys · 10 sells 10 filings BGNE BGNE 0 buys · 1 sell 1 filing

Recent filings

ONCSALE BeOne Medicines AG View filing → $432K
1,647 sh across 2 lots
Exec Jun 16 2025
Filed Jun 18 2025 · 5:30 PM ET ONCSALE BeOne Medicines AG View filing → $150K
600 sh × $250.71
Exec Jun 6 2025
Filed Jun 10 2025 · 5:30 PM ET BGNESALE BeiGene, Ltd. View filing → $1.3M
5,000 sh across 6 lots
Exec Feb 21 2025
Filed Feb 25 2025 · 5:30 PM ET